Arvinas is a biotechnology company singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins. The company’s proprietary PROTACs (proteolysis-targeting chimeras) are designed to harness the body’s own natural protein disposal system, the proteasome, to degrade and remove disease-causing proteins. This approach has transformative potential for patients living with cancers and other difficult-to-treat diseases, as it can address proteins previously considered ‘undruggable’ by traditional methods.

Founded with a strong scientific foundation rooted in research from Yale University, Arvinas has built a robust pipeline of investigational therapies, primarily targeting receptors associated with prostate and breast cancers. By leveraging induced proximity, Arvinas’ medicines act as molecular matchmakers, bringing together a disease-causing protein and the cell’s own degradation machinery to eliminate the target protein. This innovative strategy allows Arvinas to target a broader range of disease-related proteins compared to conventional small molecule inhibitors.

Arvinas is known for its bold scientific vision and culture, emphasizing patient-centric innovation and collaboration with leading drug development companies. The company’s mission is not only to advance scientific discovery but to realize the full potential of targeted protein degradation technology, aiming to revolutionize treatment paradigms across multiple disease areas.

Despite initial skepticism from the biotech industry, Arvinas has successfully bridged the gap between academic research and commercial drug development. Its approach has garnered significant interest from the investment and pharmaceutical communities, enabling strategic partnerships and advancing promising candidates through clinical evaluation. Arvinas continues to work tirelessly to unlock the capabilities of PROTACs, striving to bring new therapeutic possibilities to patients who need them most.